Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages

x

This content is available also in other languages

April 17, 2002 | Corporate News | English

To financial analysts and fund managers

  • Change in management at Tecan Corporate Communications and Investor Relations

We would like to inform you that as of today Gaby Bachofner, Head of Corporate Communications and Investor Relations at Tecan Group Ltd, is leaving the company to pursue other interests.

Effective immediately, Christophe Lamps of Rochat & Partners in Geneva will assume responsibility for Tecan Public Relations activities.

If you have any questions concerning Tecan Investor Relations or other business activities, contact details are provided below.

Tecan (www.tecan.com) is a leading player in the fast growing Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2001, Tecan achieved sales of CH 361.9 million (USD 214.1 million; EUR 239.6 million).  Registered shares of Tecan Group are traded on the Swiss SWX stock exchange (TK: TECN / Reuters: TECZn.S / Valor : 1210019).  

For more information, please contact :

Tecan:

Dr. Emile C. Sutcliffe
Chief Executive Officer
Tel.: +41 (0)44 922 81 11
Fax: +41 (0)44 922 88 89
e-mail: investor@tecan.com
Internet: www.tecan.com

Rochat & Partners:

Rochat & Partners
Christophe Lamps 
Tel.: +41 (0)22 786 54 55
Fax: +41 (0)22 786 54 58
e-mail: clamps@rochat-pr.ch

Downloads: